Literature DB >> 15668981

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.

Hirokazu Shiraishi1, Masakatsu Motomura, Toshiro Yoshimura, Takayasu Fukudome, Taku Fukuda, Yoko Nakao, Mitsuhiro Tsujihata, Angela Vincent, Katsumi Eguchi.   

Abstract

Muscle-specific tyrosine kinase (MuSK) antibodies are found in some patients with "seronegative" myasthenia gravis (MG), but how they cause myasthenic symptoms is not clear. We visualized acetylcholine receptors (AChRs) and complement component 3 (C3) in muscle biopsies from 10 Japanese MG patients with MuSK antibodies, compared with 42 with AChR antibodies. The AChR density was not significantly decreased in MuSK antibody (Ab)-positive end-plates compared with AChR antibody-positive end-plates, and C3 was detected in only two of eight MuSK Ab-positive patients. MuSK antibodies do not appear to cause substantial AChR loss, complement deposition, or morphological damage. Effects on MuSK function need to be explored.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668981     DOI: 10.1002/ana.20341

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 2.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

3.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

4.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

5.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 6.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

7.  LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.

Authors:  Bisei Ohkawara; Macarena Cabrera-Serrano; Tomohiko Nakata; Margherita Milone; Nobuyuki Asai; Kenyu Ito; Mikako Ito; Akio Masuda; Yasutomo Ito; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

Review 8.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

9.  Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders.

Authors:  H Nakamura; T Usa; M Motomura; T Ichikawa; K Nakao; E Kawasaki; M Tanaka; K Ishikawa; K Eguchi
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.